Nanjing Chai Thai Tian Qing

We entered into a collaboration agreement in January 2019 with NJCTTQ, a pharmaceutical company specializing in research and development, production and commercialization of drugs for cardiovascular diseases, tumors, perioperative care, gastrointestinal disorders and urologic diseases headquartered in Nanjing, China.ABP-150 targeting Claudin18.2/CD3 is being developed under this collaboration. We granted NJCTTQ the commercial rights of ABP-150 in China and Thailand while we hold the commercial rights of the rest of world exclusively.